Background: The use of resveratrol as a dietary supplement is limited because it is easily\noxidized and, after oral ingestion, it is metabolized into enterocytes and hepatocytes. Thus, new\nformulations are needed in order to improve its oral bioavailability. Objective: The objective of\nthis study was to develop and characterize a gastro-resistant formulation of resveratrol for oral\nadministration as a dietary supplement. Method: Resveratrol was encapsulated in Eudragit-coated\npectin-alginate microparticles. Results: The microparticle size was about 1450 .., with an\nencapsulation efficiency of 41.72% ± 1.92%. The dissolution assay conducted, as specified in the\nEuropean Pharmacopoeia for delayed-release dosage forms, revealed that our microparticles were\ngastro-resistant, because the resveratrol percentage released from microparticles in acid medium was\nless than 10%. In addition, the high-performance liquid chromatographic (HPLC) method developed\nfor resveratrol content quantification in the microparticles was validated according to International\nCouncil for Harmonisation (ICH) Q2 (R1) guidelines. Finally, the biological activity of resveratrol was\ninvestigated in 3T3-L1 mature adipocytes, concluding that the encapsulation process does not affect\nthe activity of resveratrol. Conclusion: In summary, the gastro-resistant microparticles developed\ncould represent a suitable method of including resveratrol in dietary supplements and in functional\nfoods used in obesity therapy.
Loading....